H.C. Wainwright launched coverage of IDEAYA Biosciences (NASDAQ:IDYA) with a “buy” rating and $13 price target. The stock closed at $3.59 on April 3. Analyst Edward White writes that IDE196 is the company’s potent...
H.C. Wainwright initiated coverage of Swiss-based Molecular Partners (SWX:MOLN) with a “buy” rating and price target of CHF29. The stock closed at CHF17.54 on April 1. Molecular Partners is developing targeted therapies...
H.C. Wainwright lowered its price target for AVEO Pharmaceuticals (NASDAQ:AVEO) to $4 from $6, but reiterated a “buy” rating, citing discontinuation of the company’s ficlatuzumab program because of COVID-19 and reduced...
H.C. Wainwright lowered its price target for Aileron Therapeutics (NASDAQ:ALRN) to $3 from $6, citing the removal of lead drug candidate, ALRN-6924, in combination with Ibrance in murine double minute 2 (MDM2) gene...
H.C. Wainwright lowered its price target for BeyondSpring (NASDAQ:BTSI) to $30 from $41, but reiterated a “buy” rating, citing a higher discount rate to account from increased uncertainty of COVID-19’s impact on...
H.C. Wainwright initiated coverage of AB Science (Euronext – FR0010557264 – AB) with a “buy” rating and price target of €9.00. The stock closed at €6.78 on March 27. AB Science’s lead product, masitinib, is...
H.C. Wainwright downgraded PDS Biotechnology (NASDAQ:PDSB) to “neutral” from “buy” and removed its price target, citing recent significant dilution and lack of meaningful catalysts over the remainder of the year “prompt...
H.C. Wainwright downgraded aTyr Pharma (NASDAQ:LIFE) to “neutral” from “buy” and removed its price target, citing delays in topline results from a Phase 1b/2a trial of ATYR1923 for the treatment of sarcoidosis, an...
H.C. Wainwright slashed its price target for Tracon Pharmaceuticals (NASDAQ:TCON) to $6 from $13, but reiterated its “buy” rating, after the company and partner, Santen Pharmaceutical, discontinued development of DE-122...
H.C. Wainwright initiated coverage of electroCore (NASDAQ:ECOR) with a “buy” rating and $2 price target. The stock closed at 65 cents on March 9. electroCore is commercializing its lead product, gammaCore, the only FDA...